论文部分内容阅读
目的探讨125I粒子植入联合肝动脉栓塞化疗治疗原发性肝癌的疗效与安全性。方法 38例经病理确诊的原发性肝癌患者,先行肝动脉栓塞化疗,2周后用放射性粒子计算机治疗计划系统制定治疗方案,在CT引导下经皮穿刺,将125I粒子植入肝脏病灶内。粒子植入后定期行肝动脉栓塞化疗。粒子植入前后进行血常规、肝功能检测,每2个月复查1次CT和X线平片。结果 38例放射性粒子植入按计划植入到位,植入过程无粒子丢失。1周后血常规、肝功能与植入前接近,无严重并发症。治疗4个月总有效率94.74%。结论原发性肝癌125I粒子植入联合肝动脉栓塞化疗提高了局部控制率,且安全性、可操作性确切。
Objective To investigate the efficacy and safety of 125I seed implantation and hepatic arterial chemoembolization in the treatment of primary liver cancer. Methods Thirty-eight patients with primary liver cancer diagnosed by pathology were treated with transcatheter hepatic arterial chemoembolization (TACE). Two weeks later, they were treated with radioactive particle computerized therapy planning system. Percutaneous puncture was performed under CT guidance to implant 125I particles into liver lesions. Perioperative hepatic arterial chemoembolization after implantation of particles. Before and after particle implantation, blood tests and liver function tests were performed. CT and X-ray films were reviewed every 2 months. Results 38 cases of radioactive particles were implanted as planned and no particles were lost during implantation. After 1 week of blood, liver function and before the close, no serious complications. The total effective rate was 94.74% after 4 months of treatment. Conclusion The primary hepatic carcinoma with 125I seed implantation combined with transcatheter hepatic arterial chemoembolization improves the local control rate and is safe and operable.